Official Title: “A Non-Interventional Study of Cough Variant Asthma Treatment With Pulmicort®Respules® in Patient Aged 5-Year Old or Younger in Outpatient Department”

This open label, non-interventional study is to show the efficacy of Pulmicort®Respules® in cough variant asthma in patient aged 5-year old or younger in outpatient department

Study Type: Observational

Study Design: Other, Prospective

Primary Measures

• Patient Symptom Score
  • Time Frame: 7 weeks (plus or minus 3 days )
    Safety Issue?: No

Secondary Measures

• Patient Compliance Report
  • Time Frame: 7 weeks (plus or minus 3 days )
    Safety Issue?: No
• Investigator Assessment Report
  • Time Frame: 7 weeks (plus or minus 3 days )
    Safety Issue?: No

Inclusion Criteria:

• Provision of informed consent
• Patient who has been prescribed Pulmicort® Respules® according to physician's judgement, irrespective of the inclusion in the study.
• The usage of Pulmicort® Respules® follows local authorised package insert.

Exclusion Criteria:

• Allergy to any ingredient of Pulmicort® Respules®
• With history of Leukotriene Modifier (LM) usage prior to 2 weeks of recruitment or following plan.
• Have used systemic/inhaled steroid prior to 2 weeks of recruitment

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: N/A

Maximum Age for this Clinical Trial: 5 Years

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Sponsor: AstraZeneca

Overall Clinical Trial Officials and Contacts

Hong Jianguo, Professor Principal Investigator Shanghai Jiao Tong University Affiliated First People's Hospital,  

Overall Contact: AstraZeneca China Clinical Study Information +8621 52564555 tracy.shi@AstraZeneca.com

Information obtained from ClinicalTrials.gov on September 04, 2008

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00660114

Study ID Number: NIS-RCN-PUL-2008/1

ClinicalTrials.gov Identifier: NCT00660114

Health Authority: China: State Food and Drug Administration